Oral Semaglutide Tracker
Track the New Weight Loss Pill — No Injections Required
Novo Nordisk's high-dose oral semaglutide weight loss tablet was approved in January 2026. The OASIS 4 trial showed 13.6% weight loss at 64 weeks. Track daily doses, weight, and side effects with Shotlee — free forever.
What is Oral Semaglutide for Weight Loss?
The FDA approved Novo Nordisk's high-dose oral semaglutide tablet for chronic weight management in January 2026 — the first GLP-1 pill specifically indicated for obesity. This uses the same SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate) absorption technology as Rybelsus, but at doses of 25mg and 50mg — far higher than Rybelsus's maximum 14mg for diabetes.
The OASIS 4 clinical trial demonstrated 13.6% mean body weight loss at 64 weeks — significantly better than injectable Wegovy and approaching results of injectable semaglutide at 2.4mg/week in similar patient populations.
Key requirement: Like Rybelsus, this tablet must be taken on an empty stomach with ≤4oz of water, 30 minutes before any food or other medications. This makes timing tracking with Shotlee especially important to ensure consistent absorption.
FAQ
What is the new oral semaglutide weight loss pill?
FDA-approved January 2026 for obesity. High-dose oral semaglutide (25mg or 50mg daily) using SNAC technology. The OASIS 4 trial showed 13.6% weight loss at 64 weeks. Different from Rybelsus (lower dose, diabetes only).
How is this different from Rybelsus?
Much higher doses (25–50mg vs 14mg max for Rybelsus) produce substantially greater weight loss (~13.6% vs ~4%). Also FDA-approved specifically for obesity, not just diabetes.
Does it still require fasting?
Yes — must be taken on an empty stomach with ≤4oz water, 30 minutes before food. Shotlee's daily reminders help you build this habit consistently for optimal absorption.